ANL 30.68 Increased By ▲ 1.83 (6.34%)
ASC 14.94 Decreased By ▼ -0.21 (-1.39%)
ASL 23.90 Decreased By ▼ -0.25 (-1.04%)
AVN 92.00 Decreased By ▼ -5.95 (-6.07%)
BOP 9.14 Decreased By ▼ -0.16 (-1.72%)
BYCO 10.25 Decreased By ▼ -0.10 (-0.97%)
DGKC 135.60 Increased By ▲ 0.10 (0.07%)
EPCL 50.00 Increased By ▲ 0.02 (0.04%)
FCCL 24.62 Decreased By ▼ -0.54 (-2.15%)
FFBL 24.25 Decreased By ▼ -0.97 (-3.85%)
FFL 15.60 Decreased By ▼ -0.44 (-2.74%)
HASCOL 10.74 Decreased By ▼ -0.33 (-2.98%)
HUBC 85.20 Increased By ▲ 0.20 (0.24%)
HUMNL 7.35 Decreased By ▼ -0.35 (-4.55%)
JSCL 24.85 Decreased By ▼ -0.90 (-3.5%)
KAPCO 37.85 Increased By ▲ 0.40 (1.07%)
KEL 4.15 Decreased By ▼ -0.02 (-0.48%)
LOTCHEM 14.78 Decreased By ▼ -0.35 (-2.31%)
MLCF 46.60 Decreased By ▼ -0.58 (-1.23%)
PAEL 38.25 Decreased By ▼ -1.15 (-2.92%)
PIBTL 11.80 Decreased By ▼ -0.24 (-1.99%)
POWER 10.50 Decreased By ▼ -0.15 (-1.41%)
PPL 90.55 Decreased By ▼ -0.45 (-0.49%)
PRL 26.10 Decreased By ▼ -0.59 (-2.21%)
PTC 8.95 Decreased By ▼ -0.10 (-1.1%)
SILK 1.40 Decreased By ▼ -0.05 (-3.45%)
SNGP 38.10 Decreased By ▼ -0.65 (-1.68%)
TRG 141.10 Decreased By ▼ -4.60 (-3.16%)
UNITY 31.50 Decreased By ▼ -1.40 (-4.26%)
WTL 1.57 Decreased By ▼ -0.04 (-2.48%)
BR100 4,936 Decreased By ▼ -22.94 (-0.46%)
BR30 25,403 Decreased By ▼ -330.65 (-1.28%)
KSE100 45,865 Decreased By ▼ -100.6 (-0.22%)
KSE30 19,173 Decreased By ▼ -26.07 (-0.14%)
World

New warning on vaccine supplies sparks EU concern

  • The European Union has so far approved vaccines from Pfizer and its German partner BioNTech as well as from US company Moderna.
23 Jan 2021

PARIS: A warning from AstraZeneca that initial supplies of its Covid vaccinations to Europe will be lower than expected has sparked new concern over the rollout of inoculations, with some countries planning for a sharp drop in deliveries.

Friday's announcement by the British pharmaceutical firm followed another last week by Pfizer, which said it would delay shipments of its vaccine for up to a month due to works at its key plant in Belgium.

The companies' warnings come with worry deepening over new Covid-19 variants, particularly one that emerged in Britain and which is more infectious than the original strain.

Overall, Europe has now recorded more than 692,000 deaths and nearly 32 million infections.

The European Union has so far approved vaccines from Pfizer and its German partner BioNTech as well as from US company Moderna.

It has not yet approved the vaccine from AstraZeneca and its partner the University of Oxford, but is expected to make a decision by January 29.

AstraZeneca said in its statement that if EU approval is granted, the "initial volumes will be lower than anticipated", although the start would not be delayed.

The company blamed "reduced yields at a manufacturing site within our European supply chain."

It said it would in any case supply the EU with "millions of doses" while ramping up production in February and March.

The announcement led to "deep dissatisfaction" from EU member states, which "insisted on a precise delivery schedule," said European health commissioner Stella Kyriakides.

Austrian health minister Rudolf Anschober called it "very, very bad news" and said his country would receive in February only slightly more than half of the 650,000 AstraZeneca doses it had anticipated.

Lithuania said it was expecting an 80 percent reduction in AstraZeneca doses in the first quarter.

Some government officials however sought to reassure their countries -- weary and battered by months of the pandemic and already on edge over slow vaccination rollouts.

"We have new vaccines on the way. We have Pfizer, which is increasing its production capacities," French industry minister Agnes Pannier-Runacher told French radio.

"We had indicated a million people vaccinated by the end of January. We are at 950,000 today, so that objective will be surpassed."

The EU had initially ordered up to 400 million doses of the AstraZeneca vaccine.

In total, the EU has secured contracts for more than two billion vaccine doses for a total population of 450 million.

The AstraZeneca vaccine has the advantage of being cheaper to produce than that of its rivals as well as being simpler to store and transport.

German health minister Jens Spahn also sought to downplay the announcement's effect, saying that after the jab's expected approval in a week's time "there will be AstraZeneca deliveries in February."

Though he added: "How much, we must still clarify with AstraZeneca and the European Union in the days ahead."

Sweden's national vaccination coordinator Richard Bergstrom said he expects his country to receive around 700,000 doses in the first month after the vaccine is authorised compared to one million expected initially.

Norway, which is not an EU member but which follows decisions made by the bloc's EMA regulator, expressed "disappointment."

The country's FHI health authority now plans to receive only 200,000 AstraZeneca doses in February -- far less than the 1.12 million initially expected.

Meanwhile, the Pfizer delay announced last week was continuing to cause criticism.

Pfizer said on January 15 that modifications at its Puurs factory were necessary to ramp up vaccine production capacity from mid-February.

"We believe that Pfizer is currently at fault," Domenico Arcuri, Italy's special commissioner for the pandemic, said in La Stampa newspaper on Saturday, confirming the country planned to pursue legal action against the company.

"The 20-percent reduction in Pfizer vaccine supplies is not an estimation, but a sad certainty," he said, adding that Italians' health was not "negotiable".

French European affairs minister Clement Beaune on Friday called on Pfizer to "honour its commitments."